supp.fit

N-Acetyl Cysteine: study protocols

250 study groups say how much N-Acetyl Cysteine participants took a day. These are the doses the studies gave. They are not a recommendation.

N-Acetyl Cysteine: what the research found →

Dose per serving from products

828 products in our catalogue print how much N-Acetyl Cysteine a serving holds.

Most common: 500 mg to 1 g, 31% of 828 products.

Dose per servingProducts
10 mg or less
23
10 mg to 25 mg
35
25 mg to 50 mg
63
50 mg to 100 mg
117
100 mg to 250 mg
141
250 mg to 500 mg
144
500 mg to 1 g
260
1 g to 2.5 g
45

Dose per serving from research

242 study groups in 197 studies say how much N-Acetyl Cysteine participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 70% of 242 study groups.

Daily doseStudy groups
250 mg or less
12
250 mg to 500 mg
7
500 mg to 1 g
38
1 g to 2.5 g
170
2.5 g to 5 g
12
over 5 g
3

Commonly used together

34 of 250 study groups took N-Acetyl Cysteine with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Vitamin E
9
Vitamin C
8
Selenium
6
Vitamin B12
5

250 study groups

Study
Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure
2002 · acetylcysteine group · Adults with chronic renal insufficiency undergoing a coronary procedure; age and sex not stated
800 mg—60
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies
2012 · G2, pancreatic cancer · Adults aged 18–65 with unresectable locally advanced pancreatic adenocarcinoma
800 mg8 weeks30
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies
2012 · G2, non-small-cell lung cancer · Adults aged 18–65 with unresectable locally advanced non-small-cell lung cancer
800 mg8 weeks30
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies
2012 · G2, hormone-refractory metastatic prostate cancer · Men aged 18–65 with hormone-refractory metastatic prostate cancer
800 mg8 weeks30
N-acetylcysteine Restored Heart Rate Variability and Prevented Serious Adverse Events in Transfusion-dependent Thalassemia Patients: a Double-blind Single Center Randomized Controlled Trial
2020 · NAC group · Adults aged 18–50 with transfusion-dependent thalassemia
600 mg26 weeks30
N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD
1999 · standard therapy plus NAC · Patients with moderate to severe COPD
600 mg26 weeks—
Effect of oral N-acetyl cysteine on recurrent preterm labor following treatment for bacterial vaginosis
2009 · NAC group · Pregnant women at 16–18 weeks with one previous preterm birth, recently treated successfully for bacterial vaginosis
600 mg——
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial
2014 · N-acetylcysteine group · Adults aged 40–80 years with moderate-to-severe COPD
1.2 g1 year504
Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study
2019 · NAC · Adults with chronic obstructive pulmonary disease; smoking status varied
1.2 g—482
N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial
2007 · clomiphene citrate plus N-acetyl cysteine · Women with polycystic ovary syndrome
1.2 g5 days470
Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial
2024 · N-acetylcysteine group · Adults aged 40–80 with mild-to-moderate COPD (GOLD stage 1–2)
1.2 g88 weeks464
Effect of N-acetylcysteine against Vancomycin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial
2020 · drug (NAC) group · Patients receiving vancomycin for any indication
1.2 g10 days84
Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial
2019 · N-acetylcysteine group · Adults aged 18–80 with idiopathic or post-infective bronchiectasis and at least two exacerbations in the past year, stable for at least 4 weeks before randomisation
1.2 g1 year81
Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial
2022 · NAC prophylaxis cohort (group A) · Patients aged 15–60 years with acute leukemia in complete remission undergoing first haploidentical HSCT and pre-HSCT bone-marrow endothelial cell percentage <0.1%
1.2 g12 weeks80
N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome
2005 · NAC group (group I) · Women aged 18–39 with clomiphene citrate-resistant PCOS undergoing infertility therapy
1.2 g5 days75
N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy
2009 · Group 2 · Patients with eGFR 30–60 mL/min/1.73 m² undergoing coronary angiography
1.2 g2 days73
N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy
2009 · Group 3 · Patients with eGFR 30–60 mL/min/1.73 m² undergoing coronary angiography
1.2 g2 days72
The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial
2003 · acetylcysteine group · Adults with end-stage renal failure undergoing maintenance hemodialysis; mean age 62 years, 76 male and 58 female across the trial
1.2 g63 weeks64
Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD
2014 · NAC · Chinese adults with spirometry-confirmed stable COPD; mean age 70.8 years; 93.2% men
1.2 g1 year52
Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine
2000 · acetylcysteine group · Patients with chronic renal insufficiency undergoing computed tomography with a nonionic, low-osmolality contrast agent
1.2 g—41
Does nebivolol prevent contrast-induced nephropathy in humans?
2012 · Group I · Patients scheduled for coronary angiography and ventriculography; age and sex not reported
1.2 g4 days40
Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study
2010 · group A · women with clomiphene citrate-resistant polycystic ovary syndrome who underwent unilateral laparoscopic ovarian drilling
1.2 g5 days30
Effect of antioxidant therapy on hospital stay and complications in patients with early acute pancreatitis: a randomised controlled trial
2009 · SMT + AO · Adults admitted within 72 hours of onset of pain with acute pancreatitis; age and sex not specified
600 mg—23
Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results
2008 · N-acetylcysteine (NAC) · Patients with moderately impaired kidney function receiving low-osmolar, non-ionic contrast media
1.2 g2 days19
Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study)
2020 · NAC Group · Adults aged 18 years or older, any gender, hospitalized with HIV-associated pulmonary tuberculosis
1.2 g8 weeks18
[N-acetylcystein in the therapy of chronic bronchitis]
2002 · NAC added to standard antibiotic therapy · Patients with acute exacerbation of chronic bronchitis and positive bacterial culture in sputum; mean age 66 years; 16 male and 8 female
1.2 g——
Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography
2003 · acetylcysteine · Patients with serum creatinine ≥1.5 mg/dL undergoing cardiac catheterization, with mild to moderate renal impairment
1.2 g——
Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity
2004 · Standard-dose group (SD Group) · Patients with chronic renal insufficiency undergoing contrast-agent procedures
1.2 g——
Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial
2007 · Sodium chloride plus oral NAC · Patients with baseline creatinine >1.2 mg/dL undergoing cardiovascular procedures
1.2 g——
N-Acetylcysteine as an adjuvant to clomiphene citrate for successful induction of ovulation in infertile patients with polycystic ovary syndrome
2012 · group 1 (CC+NAC) · Infertile patients with polycystic ovary syndrome; age and sex not specified
1.2 g5 days—
A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity
2015 · N-acetylcysteine (NAC) · Patients receiving amphotericin B treatment
1.2 g——
Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study
2009 · N-acetyl-cysteine group · Infertile men with idiopathic oligo-asthenoteratospermia
600 mg26 weeks118
Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status
2009 · study group · men with idiopathic infertility
600 mg90 days60
Effects of N-acetyl-cysteine supplementation on sperm quality, chromatin integrity and level of oxidative stress in infertile men
2019 · NAC treatment · Men aged 25–40 years with infertility and terato-asthenozoospermia
600 mg90 days50
N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial
2013 · NAC group · Children and adolescents with chronic nail biting
800 mg60 days21
Preventing cisplatin induced ototoxicity by N-acetylcysteine and salicylate
2010 · N-acetylcysteine group · Adults with solid organ tumors receiving cisplatin chemotherapy; mean age 37 years, range 29–71; both sexes
600 mg—18
A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis
2009 · 700 mg NAC (low-dose) · Patients older than 16 years with cystic fibrosis and stable disease
700 mg12 weeks11
N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study
2008 · group A · Patients with mild to moderate ulcerative colitis; age and sex not specified
800 mg4 weeks—
N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome
2024 · NAC group · Women aged 21–38 with PCOS and anovulation or oligo-ovulation undergoing ovulation induction
1.8 g5 days115
N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up
2004 · N-acetylcysteine (NAC) · Patients with moderate renal dysfunction undergoing PCI or coronary angiography with a high likelihood of ad hoc PCI
4 g1 day95
Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis
2024 · standard therapy with NAC · Adults with moderate or far-advanced pulmonary tuberculosis
2.4 g16 weeks70
N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial
2013 · SN group · Patients with renal dysfunction undergoing diagnostic-therapeutic procedures with low-osmolar contrast media
1.2 g2 days38
N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial
2016 · Group A · High-risk patients undergoing elective cardiac catheterization
2.4 g—30
Effects of antioxidants on glutathione levels and clinical recovery from the malnutrition syndrome kwashiorkor--a pilot study
2005 · N-acetylcysteine group · Children with severe kwashiorkor
200 mg20 days—
N-acetylcysteine in Acute Organophosphorus Pesticide Poisoning: A Randomized, Clinical Trial
2016 · N-acetylcysteine group · Patients with acute organophosphorus pesticide poisoning; age and sex not specified
1.8 g3 days—
A randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease
2022 · AS-1,200 · Patients with frequent-exacerbation COPD following an acute exacerbation
1.2 g90 days—
N-Acetylcysteine as Prophylactic Therapy for Transplantation-Associated Thrombotic Microangiopathy: A Randomized, Placebo-Controlled Trial
2022 · oral NAC · Patients scheduled for allogeneic hematopoietic stem cell transplantation
50 mg/kg39 days—
Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study
2009 · selenium plus N-acetyl-cysteine group · Infertile men with idiopathic oligo-asthenoteratospermia
600 mg26 weeks116
N-acetylcysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test
2008 · group 1 (N-acetylcysteine) · Patients with bronchiolitis obliterans due to sulfur mustard exposure and bronchiolitis obliterans syndrome class 0
1.2 g120 days72
Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis
1994 · NAC · Patients with mild chronic bronchitis; age and sex not reported
1.2 g22 weeks59
Fluoxetine versus N-acetylcysteine in reducing craving in Indian men with alcohol dependence syndrome: a randomised controlled trial
2025 · N-acetylcysteine (NAC) · Men aged 18 to 65 years with alcohol dependence syndrome who had maintained at least 7 days of alcohol abstinence
1.2 g12 weeks50
[Clinical efficacy of tetrandrine combined with acetylcysteine effervescent tablets in treatment of silicosis]
2013 · treatment group · Adults with silicosis; age and sex not reported
1.2 g—49
Effects of N-acetylcysteine supplementation on disease activity, oxidative stress, and inflammatory and metabolic parameters in rheumatoid arthritis patients: a randomized double-blind placebo-controlled trial
2022 · NAC group · Adults with rheumatoid arthritis; age and sex not specified
1.2 g90 days37
The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study
2015 · NAC group (crossover supplement phase) · Methamphetamine-dependent volunteers
1.2 g4 weeks32
Administration of maximum dose of mucolytic solution before upper endoscopy - a double-blind, randomized trial
2023 · A · Adults over 18 years undergoing diagnostic gastroscopy
600 mg1 day30
N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study
2007 · open-label NAC · Adults with DSM-IV pathological gambling; 12 of the 27 participants were women
1.48 g8 weeks27
Evaluating the Effect of Oral N-acetylcysteine as an Adjuvant Treatment on Clinical Outcomes of Patients with Rheumatoid Arthritis: A Randomized, Double Blind Clinical Trial
2018 · NAC group · Adults with active rheumatoid arthritis
1.2 g12 weeks27
Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study
2009 · NAC treatment · Adults older than 40 years with moderate-to-severe COPD
1.2 g6 weeks24
N-acetylcysteine in chronic blepharitis
2002 · therapy group · Patients with chronic posterior blepharitis
300 mg120 days22
N-acetylcysteine supplementation controls total antioxidant capacity, creatine kinase, lactate, and tumor necrotic factor-alpha against oxidative stress induced by graded exercise in sedentary men
2011 · NAC supplement group · Healthy, sedentary, nonathletic men aged 20–24 years
1.2 g7 days18
Priming of beta-2 agonist and antimuscarinic induced physiological responses induced by 1200mg/day NAC in moderate to severe COPD patients: A pilot study
2014 · NAC treatment · Adults with moderate-to-very severe COPD; age and sex not reported
1.2 g15 days15
Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals
2006 · N-acetylcysteine condition · Adults aged 23–45, six males and seven females, with cocaine dependence who were not seeking treatment
1.2 g3 days13
Effect of N-acetylcysteine on cycling performance after intensified training
2014 · NAC · Well-trained triathletes undergoing strenuous physical training; age and sex not reported
1.2 g9 days10
Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol
2020 · 1.2 g/day n-acetylcysteine condition · Adults aged 21–55 with moderate to severe alcohol use disorder
1.2 g5 days9
N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study
2007 · NAC during double-blind phase · Responders with DSM-IV pathological gambling from the open-label phase
1.48 g6 weeks6
Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD
2008 · N-acetylcysteine (NAC) · Adults with mild-to-moderate COPD (GOLD class 1–2) who were current smokers with at least 10 pack-years
1.2 g10 days—
Modulatory effect of N-acetylcysteine on pro-antioxidant status and haematological response in healthy men
2010 · NAC · Healthy men; age range not reported
1.2 g9 days—
A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders
2013 · N-Acetylcysteine + risperidone · Children aged 3.5–16 years, both sexes, with autism spectrum disorder
1.2 g8 weeks—
Comparison of the effects of N-acetyl-cysteine and ginseng in prevention of noise induced hearing loss in male textile workers
2014 · Group I · Male textile workers exposed to continuous occupational noise
1.2 g2 weeks—
Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial
2018 · NAC group · Patients with chronic schizophrenia receiving conventional antipsychotic medication; age and sex not specified
1.2 g12 weeks—
Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study
2020 · low dose group · Breast cancer patients receiving adjuvant paclitaxel
1.2 g12 weeks—
Study of the Effects of N-acetylcysteine on Inflammatory Biomarkers and Disease Activity Score in Patients with Rheumatoid Arthritis
2021 · NAC group · Patients with active rheumatoid arthritis; age and sex not reported
1.2 g8 weeks—
Men suffering from category III chronic prostatitis may benefit from N-acetylcysteine as an adjunct to alpha-blockers
2022 · NAC treatment group · Men with category III chronic prostatitis and NIH-CPSI total score of 15 or more
1.2 g12 weeks—
Randomized Clinical Trial of Antioxidant Therapy Patients with Septic Shock and Organ Dysfunction in the ICU: SOFA Score Reduction by Improvement of the Enzymatic and Non-Enzymatic Antioxidant System
2023 · Group 3 (NAC) · Adults older than 18 years of any gender with septic shock admitted to the ICU
1.2 g5 days—
N-Acetyl Cysteine as an Add-on Therapy is Useful in Treating Acute Lumbar Radiculopathy Caused by Disc Herniation: Results of a Randomized, Controlled Clinical Trial
2023 · NAC group · Patients with acute lumbar radiculopathy associated with disc herniation
1.2 g8 weeks—
Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment
1997 · NAC group · Adults of both sexes; 78% were aged 65 years or older, and 62% had nonrespiratory chronic degenerative diseases; people with chronic respiratory diseases were excluded.
1.2 g26 weeks—
N-acetylcysteine and contrast-induced nephropathy in primary angioplasty
2006 · double dose of N-acetylcysteine · Patients with acute myocardial infarction undergoing primary angioplasty
2.4 g2 days119
N-acetylcysteine and contrast-induced nephropathy in primary angioplasty
2006 · standard dose of N-acetylcysteine · Patients with acute myocardial infarction undergoing primary angioplasty
1.2 g2 days116
N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial
2013 · BN group · Patients with renal dysfunction undergoing diagnostic-therapeutic procedures with low-osmolar contrast media
1.2 g2 days43
N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial
2016 · Group B · High-risk patients undergoing elective cardiac catheterization
1.2 g—30
Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial
1999 · group C · Interferon-naive patients with chronic hepatitis C; age and sex not reported
1.8 mg24 weeks8
A randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease
2022 · AS-600 · Patients with frequent-exacerbation COPD following an acute exacerbation
600 mg90 days—
The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial
2011 · open-label NAC treatment phase · Adults with bipolar disorder and moderate depression
2 g8 weeks149
The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial
2018 · NAC · Adults aged 18–50 seeking treatment for cannabis dependence; both sexes
2.4 g12 weeks142
N-Acetylcysteine for the Treatment of Co-Occurring Posttraumatic Stress Disorder and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial
2025 · NAC · Adults aged 21–65 years with current PTSD and alcohol use disorder
2.4 g12 weeks93
High-dose acetylcysteine in idiopathic pulmonary fibrosis
2005 · acetylcysteine · Adults with idiopathic pulmonary fibrosis
1.8 g1 year92
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial
2009 · NAC · Adults aged 18–75 with idiopathic pulmonary fibrosis and a histological or radiological pattern typical for usual interstitial pneumonia
1.8 g1 year80
Therapeutics effect of N-acetyl cysteine on mustard gas exposed patients: evaluating clinical aspect in patients with impaired pulmonary function test
2008 · Group 1 (NAC) · Patients with bronchiolitis obliterans due to sulfur mustard exposure, in bronchiolitis obliterans syndrome classes 1 and 2
1.8 g120 days72
A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents
2012 · N-acetylcysteine group · Adolescents aged 15–21 with cannabis dependence
2.4 g8 weeks58
Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation
2016 · NAC group · Participants aged 15–21 with marijuana dependence who used marijuana regularly and were interested in cessation treatment; participants with alcohol dependence were excluded.
2.4 g8 weeks45
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
2018 · NAC · Men and women aged 18–40 with early psychosis and less than 12 months of treatment for psychosis
2.7 g26 weeks31
Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial
2021 · NAC · Adults with bipolar disorder experiencing a current acute depressive episode
2 g16 weeks31
Administration of maximum dose of mucolytic solution before upper endoscopy - a double-blind, randomized trial
2023 · B · Adults over 18 years undergoing diagnostic gastroscopy
400 mg1 day30
Cognitive effects of adjunctive N-acetyl cysteine in psychosis
2017 · NAC · Participants with psychosis, including schizophrenia or bipolar disorder; age and sex not reported
2 g24 weeks27
Anti-oxidant N-acetylcysteine diminishes diesel exhaust-induced increased airway responsiveness in person with airway hyper-reactivity
2014 · diesel exhaust with N-acetylcysteine · Non-smoking adults, including individuals with baseline airway hyper-responsiveness; exposed to diesel exhaust
1.8 g6 days26
N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial
2016 · Fluvoxamine plus NAC · Patients with moderate-to-severe obsessive-compulsive disorder; age and sex not specified
2 g10 weeks22
N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study
2013 · NAC · Patients with chronic schizophrenia, in the active phase of illness, with a negative PANSS subscale score of 20 or greater; sex and age not reported
2 g8 weeks21
The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial
2023 · NAC group · Adults aged 18–60 with substance use disorder receiving methadone maintenance therapy
2.4 g12 weeks21
A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders
2016 · NAC · Veterans aged 18–65 with current substance use disorder and PTSD or subthreshold PTSD; primarily male
2.4 g8 weeks18
N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin
2016 · NAC group · Women aged 25–35 with polycystic ovary syndrome undergoing intracytoplasmic sperm injection
1.8 g6 weeks15
N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial
2019 · N-acetylcysteine arm · Adults with head and neck cancer undergoing concurrent chemoradiotherapy
2.5 g—15
The role of cystine-glutamate exchange in nicotine dependence in rats and humans
2009 · N-acetylcysteine · Adults dependent on nicotine, smoking at least 10 cigarettes per day for at least one year, in stable mental and physical health, and seeking to reduce cigarette use
2.4 g4 weeks14
Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients
2013 · NAC · Adults aged 40 years or older with moderate COPD, all categorized as GOLD stage II in the results
1.8 g90 days12
N-acetylcysteine reduces cocaine-seeking behavior and anterior cingulate glutamate/glutamine levels among cocaine-dependent individuals
2021 · NAC condition · Adults aged 18–55 years with cocaine dependence
1.8 g7 days12
Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia
2005 · N-acetylcysteine (NAC) · Healthy adults, mean age 29.1 years
100 mg/kg1 day10
A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis
2009 · 2800 mg NAC (high-dose) · Patients older than 16 years with cystic fibrosis and stable disease
2.8 g12 weeks10
Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study
2011 · NAC · Heavy smokers attempting to quit smoking
3.6 g4 days10
Thiol-based antioxidant supplementation alters human skeletal muscle signaling and attenuates its inflammatory response and recovery after intense eccentric exercise
2013 · N-acetylcysteine (NAC) · 10 men after muscle-damaging exercise
20 mg/kg8 days10
Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol
2020 · 2.4 g/day n-acetylcysteine condition · Adults aged 21–55 with moderate to severe alcohol use disorder
2.4 g5 days9
Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus
2013 · NAC 1,200 mg twice daily · Adults with systemic lupus erythematosus; age range 20–67 years; predominantly women
2.4 g90 days8
Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus
2013 · NAC 2,400 mg twice daily · Adults with systemic lupus erythematosus; age range 20–67 years; predominantly women
4.8 g90 days8
Continuous oral N-acetylcysteine treatment and development of nitrate tolerance in patients with stable angina pectoris
1991 · ISDN + NAC · Patients with stable angina pectoris
2.4 g8 days7
The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study
2003 · NAC group · Patients with complex regional pain syndrome type I (CRPS I)
1.8 g17 weeks—
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
2008 · N-acetyl-cysteine (NAC) · Schizophrenia patients; age and sex not specified
2 g60 days—
N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial
2008 · N-acetyl cysteine (NAC) · Adults with chronic schizophrenia receiving maintenance antipsychotic medication
2 g24 weeks—
N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial
2008 · NAC · People with bipolar disorder in the maintenance phase
2 g24 weeks—
N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial
2012 · N-acetylcysteine group · Adults with treatment-refractory obsessive-compulsive disorder who had failed to respond to serotonin reuptake inhibitor treatment
2.4 g12 weeks—
Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial
2013 · NAC · Treatment-seeking adolescents aged 15–21 with cannabis dependence
2.4 g8 weeks—
N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study
2015 · NAC-treated group · Outpatients with therapy-resistant tobacco use disorder receiving smoking-focused group behavioral therapy; age and sex not reported
3 g12 weeks—
The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study
2015 · N-Acetylcysteine · Generally healthy adult nicotine-dependent smokers who smoked at least 10 cigarettes per day and were not immediately interested in quitting
2.4 g4 days—
Oral N-acetylcysteine and exercise tolerance in mild chronic obstructive pulmonary disease
2017 · NAC · Adults with mild COPD
1.8 g4 days—
Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial
2018 · S + NAC 500 · Adults undergoing upper gastrointestinal endoscopy; mean age 49 years
500 mg1 day—
Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial
2018 · S + NAC 1000 · Adults undergoing upper gastrointestinal endoscopy; mean age 49 years
1 g1 day—
The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment
2018 · N-acetylcysteine (NAC) · Men who regularly used cocaine
2.4 g25 days—
Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders
2018 · N-acetyl cysteine (NAC) · People with early-phase schizophrenia spectrum disorders; age and sex not specified
3.6 g52 weeks—
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder
2020 · NAC · Adults aged 18–50 with cannabis dependence
2.4 g12 weeks—
Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study
2020 · high dose group · Breast cancer patients receiving adjuvant paclitaxel
2.4 g12 weeks—
Who responds to a multi-component treatment for cannabis use disorder? Using multivariable and machine learning models to classify treatment responders and non-responders
2023 · N-acetylcysteine (NAC) · Adults aged 18–50 with cannabis use disorder
2.4 g12 weeks—
N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial
2023 · NAC · Participants with alcohol use disorder; age and sex not specified
2.4 g4 weeks—
Impact of Treatment with Antioxidants as an Adjuvant to Standard Therapy in Patients with Septic Shock: Analysis of the Correlation between Cytokine Storm and Oxidative Stress and Therapeutic Effects
2023 · Group 3 (NAC) · Adults over 18 years of any gender with septic shock
2.4 g5 days—
Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status
2006 · supplementation group · Pregnant women screened positive for low antioxidant status at 8 to 12 weeks of gestation
200 mg—29
Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
2017 · Group A · Adults with chronic hepatitis C receiving pegylated interferon-α-2b and ribavirin
1.8 g1 year30
Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
2017 · Group B · Adults with chronic hepatitis C receiving pegylated interferon-α-2b and ribavirin
1.8 g1 year30
Mechanical Ventilation Antioxidant Trial
2015 · vitamin C plus vitamin E plus N-acetylcysteine · critically ill adults requiring mechanical ventilation
1.2 g——
N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients
2002 · ACEI + NAC · Smoker adults aged 69 ± 5 years with hypertension, more than 10 years of smoking and more than 10 cigarettes daily
1.8 g3 weeks18
Relative bioavailability of generic and branded acetylcysteine effervescent tablets: A single-dose, open-label, randomized-sequence, two-period crossover study in fasting healthy Chinese male volunteers
2010 · Acetylcysteine crossover phase (test and reference formulations) · Healthy Chinese male nonsmokers aged 18–40 years with BMI 19–25 kg/m²
600 mg1 day24
The administration of N-acetylcysteine reduces oxidative stress and regulates glutathione metabolism in the blood cells of workers exposed to lead
2013 · NAC 2 × 400 mg per day · Healthy male workers exposed to lead
800 mg12 weeks—
A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia
2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties
600 mg90 days59
A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia
2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties
600 mg26 weeks38
Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up
2019 · AMD-M group · Adults with intermediate age-related macular degeneration; 9 male and 21 female enrolled overall, mean age 69.32 years
140 mg26 weeks15
A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia
2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties
600 mg2 weeks—
Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease
2001 · NAC group · Adults with stable chronic obstructive pulmonary disease (COPD)
600 mg1 year22
The effect of N-acetylcysteine supplementation upon viral load, CD4, CD8, total lymphocyte count and hematocrit in individuals undergoing antiretroviral treatment
2002 · NAC group · Adults with HIV-1 infection undergoing antiretroviral treatment
600 mg180 days10
N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions
2011 · Arm 1, 300 mg NAC capsule dose · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease
600 mg1 day10
Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease
2007 · NAC · Patients with hyperhomocysteinaemia and coronary artery disease; age and sex not reported
600 mg8 weeks—
Effect of N-acetyl-cysteine and hyperoxia on erythropoietin production
2011 · NAC group · Healthy volunteers; age and sex not specified
600 mg1 day—
Effect of N-acetylcysteine administration on the expression and activities of antioxidant enzymes and the malondialdehyde level in the blood of lead-exposed workers
2014 · NAC 800 mg/day · Lead-exposed workers; age and sex not specified
800 mg12 weeks—
Effect of N-acetylcysteine administration on homocysteine level, oxidative damage to proteins, and levels of iron (Fe) and Fe-related proteins in lead-exposed workers
2016 · 2 × 400 mg NAC group · Male employees exposed to lead through their work
800 mg12 weeks—
Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-A pilot study
2024 · 600 mg NAC/day · Children with obesity and biopsy-confirmed MASLD; mean age 13.6 ± 2.8 years
600 mg16 weeks—
Correlation of plasma lipidomic profiles with cardiometabolic disease in transfusion-dependent thalassemia patients with six-month N-acetylcysteine intervention: A prospective cohort study
2025 · intervention group · Thai patients with transfusion-dependent thalassemia; age and sex not reported
600 mg26 weeks—
Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity
2001 · Arm C · Healthy volunteer smokers
1.2 g12 weeks9
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial
2012 · NAC Dose 1 (600 mg twice daily) · Adults aged 25–64 with clinically stable systemic lupus erythematosus
1.2 g90 days9
Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity
2001 · Arm A · Healthy volunteer smokers
1.2 g12 weeks6
Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity
2001 · Arm B · Healthy volunteer smokers
1.2 g12 weeks4
Plasma glutathione of HIV⁺ patients responded positively and differently to dietary supplementation with cysteine or glutamine
2012 · N-acetylcysteine (NAC) supplementation · Treated patients with HIV and healthy controls; ages 20–59 years, men and women
1 g7 days—
The administration of N-acetylcysteine reduces oxidative stress and regulates glutathione metabolism in the blood cells of workers exposed to lead
2013 · NAC 2 × 200 mg per day · Healthy male workers exposed to lead
400 mg12 weeks—
Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial
2003 · acetylcysteine · Chinese adults, mean age 68 years, with stable moderate renal insufficiency undergoing elective coronary angiography with or without intervention
1.2 g2 days102
Efficacy and safety of mesenchymal stem cell in Chinese patients with chronic renal failure: A pilot study in Shandong province, China
2021 · NACys · Chinese patients with chronic renal failure and eGFR below 60 mL/min/1.73 m²
1.2 g8 weeks100
Acetylcysteine and contrast agent-associated nephrotoxicity
2002 · group A · Patients with impaired renal function undergoing coronary and/or peripheral angiography and/or angioplasty
1.2 g—92
N-Acetylcysteine effects on transforming growth factor-β and tumor necrosis factor-α serum levels as pro-fibrotic and inflammatory biomarkers in patients following ST-segment elevation myocardial infarction
2013 · NAC group · Adults aged 40–92 with ST-segment elevation myocardial infarction (STEMI)
1.2 g3 days50
N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial
2018 · NAC group · Adults aged 18–69 with bacterial community-acquired pneumonia, PSI class I–III
1.2 g10 days37
Efficacy Of N-Acetyl-Cysteine as Adjuvant Therapy for Diabetic Foot Osteomyelitis: An Open-Label Randomized Controlled Trial
2025 · NAC group · Adults aged 18 years or older with Wagner grade III or IV diabetic foot osteomyelitis and PEDIS score ≥7
1.2 g2 weeks25
Comparative Study to Evaluate the Effect of Low-Protein Diet Supplementation with Taurine and N-Acetylcysteine, N-Acetylcysteine and Pyridoxamine Dihydrochloride in Preventing the Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney Disease
2022 · NP (NAC + pyridoxamine dihydrochloride) arm · Adults with non-diabetic chronic renal failure, GFR >15 and <60 ml/min/1.73 m², receiving standard care
600 mg26 weeks24
A Pilot Study to Evaluate the Effects of Oral N-Acetyl Cysteine on Inflammatory and Oxidative Stress Biomarkers in Rheumatoid Arthritis
2019 · NAC group · Patients with rheumatoid arthritis
1.2 g12 weeks23
Effects of N-acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis
2023 · NAC group · Adults aged 18–60 with clinically definite relapsing-remitting multiple sclerosis and mild-to-moderate anxiety and depression symptoms
1.2 g8 weeks21
Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers
2002 · NAC group · Healthy smoking volunteers; age and sex not reported
1.2 g26 weeks20
Usefulness of Antioxidants as Adjuvant Therapy for Septic Shock: A Randomized Clinical Trial
2020 · NAC · Adults of either sex with septic shock
1.2 g5 days20
Adjunct N-Acetylcysteine Treatment in Hospitalized Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood: Results From the RIPENACTB Study Trial
2020 · RIPENAC (NAC group) · Adults aged 18 years or older, both sexes, hospitalized with HIV and confirmed pulmonary tuberculosis
1.2 g8 weeks18
Effect of oral N-acetylcysteine treatment on immune system in continuous ambulatory peritoneal dialysis patients
2012 · NAC group · Patients receiving continuous ambulatory peritoneal dialysis (CAPD); age and sex not specified
1.2 g8 weeks16
Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study
2010 · NAC · Adults on regular peritoneal dialysis; mean age 52 ± 13 years, 40% male
1.2 g8 weeks15
Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy
2010 · NAC group · Patients undergoing coronary angiography and/or percutaneous coronary intervention; chronic kidney disease was noted as a risk group, but was not stated as an eligibility requirement.
1.41 g—15
N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial
2012 · NAC · Men or post-menopausal women with type 2 diabetes; mean age 63.9 years
1.2 g8 days14
N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions
2011 · Arm 1, 600 mg NAC capsule dose · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease
1.2 g1 day10
Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease
2010 · Healthy control subjects · Healthy adults
1.2 g2 weeks7
N-acetylcysteine reduces oxidative stress in sickle cell patients
2012 · 1,200 mg NAC group · Adults aged 20–47 with homozygous sickle cell anemia or HbSβ0-thalassemia
1.2 g6 weeks6
N-acetylcysteine reduces oxidative stress in sickle cell patients
2012 · 2,400 mg NAC group · Adults aged 20–47 with homozygous sickle cell anemia or HbSβ0-thalassemia
1.2 g6 weeks4
Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD
2005 · group A · Adults with clinically stable COPD; mean age 65.93 years; 48 of 55 participants were male
1.2 g60 days—
N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery
2008 · Group 2 · Adults with chronic renal insufficiency (creatinine clearance ≤40 mL/min) undergoing cardiac surgery
1.2 g3 days—
N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery
2008 · Group 3 · Adults with chronic renal insufficiency (creatinine clearance ≤40 mL/min) undergoing cardiac surgery
1.2 g3 days—
The comparison of antioxidant and hematological properties of N-acetylcysteine and alpha-lipoic acid in physically active males
2009 · N-acetylcysteine (NAC) · Healthy, physically active men
1.2 g8 days—
Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease
2010 · 600 mg sustained-release NAC · Adults with end-stage renal disease
1.2 g2 weeks—
Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man
1990 · 600 mg twice daily for 5 days · Healthy subjects; age and sex not reported
1.2 g5 days—
High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study
2013 · NAC · Adults aged 50–80 years with stable COPD
1.2 g1 year—
Effect of N-acetylcysteine administration on the expression and activities of antioxidant enzymes and the malondialdehyde level in the blood of lead-exposed workers
2014 · NAC 400 mg/day · Lead-exposed workers; age and sex not specified
400 mg12 weeks—
Effect of N-acetylcysteine administration on homocysteine level, oxidative damage to proteins, and levels of iron (Fe) and Fe-related proteins in lead-exposed workers
2016 · 2 × 200 mg NAC group · Male employees exposed to lead through their work
400 mg12 weeks—
N-acetylcysteine decreases urinary level of neutrophil gelatinase-associated lipocalin in deceased-donor renal transplant recipients: a randomized clinical trial
2018 · NAC · Deceased-donor kidney transplant recipients
1.2 g5 days—
Renal protective effect of N-acetylcysteine with stepwise ramping voltage against extracorporeal shock wave lithotripsy-induced renal injury: a prospective randomized trial
2020 · Group C · Adults with a single renal stone scheduled for extracorporeal shock wave lithotripsy (ESWL); age range and sex not reported
1.2 g3 days—
Renal protective effect of N-acetylcysteine with stepwise ramping voltage against extracorporeal shock wave lithotripsy-induced renal injury: a prospective randomized trial
2020 · Group D · Adults with a single renal stone scheduled for extracorporeal shock wave lithotripsy (ESWL); age range and sex not reported
1.2 g3 days—
N-Acetylcysteine Improves Inflammatory Response in COPD Patients by Regulating Th17/Treg Balance through Hypoxia Inducible Factor-1α Pathway
2021 · treatment group · Elderly patients with stable COPD, GOLD stage C or D
1.2 g26 weeks—
A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life
2023 · NAC group · Newly diagnosed patients with tuberculosis on first-line anti-tuberculosis treatment; age and sex not specified
1.2 g4 weeks—
Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-A pilot study
2024 · 1200 mg NAC/day · Children with obesity and biopsy-confirmed MASLD; mean age 13.6 ± 2.8 years
1.2 g16 weeks—
The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection -- a pilot study
2015 · NAC group · Patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection
2.4 g30 days11
Endogenous plasma N-acetylcysteine and single dose oral bioavailability from two different formulations as determined by a new analytical method
1991 · first N-acetylcysteine formulation · adult volunteers; sex and age not reported
200 mg1 day10
Endogenous plasma N-acetylcysteine and single dose oral bioavailability from two different formulations as determined by a new analytical method
1991 · second N-acetylcysteine formulation · adult volunteers; sex and age not reported
200 mg1 day10
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial
2012 · NAC Dose 2 (1,200 mg twice daily) · Adults aged 25–64 with clinically stable systemic lupus erythematosus
2.4 g90 days9
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial
2012 · NAC Dose 3 (2,400 mg twice daily) · Adults aged 25–64 with clinically stable systemic lupus erythematosus
4.8 g90 days9
The administration of N-acetylcysteine reduces oxidative stress and regulates glutathione metabolism in the blood cells of workers exposed to lead
2013 · NAC 1 × 200 mg per day · Healthy male workers exposed to lead
200 mg12 weeks—
N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis
2025 · NAC group · Adults with moderate or far-advanced pulmonary tuberculosis
2.4 g120 days—
Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial
2015 · NAC · Adults with at least moderate renal impairment undergoing cardiac catheterisation with or without percutaneous coronary intervention; mean age 68 years, 76% male
2.4 g3 days185
N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial
2009 · high-dose NAC · Patients with pre-existing renal impairment; age and sex not reported
2.4 g—106
N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity
2004 · NAC group · Patients with chronic renal insufficiency referred for coronary and/or peripheral procedures; age and sex not reported
2.4 g—97
A comparison between the effects of metformin and N-acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome
2016 · NAC group · Women with diagnosed polycystic ovary syndrome (PCOS), without additional complications
1.8 g24 weeks46
Efficacy of N-acetylcysteine and motivational enhancement therapy for nicotine addiction: A randomized clinical trial
2025 · Intervention group · Adult male and female active smokers aged 18 or older who smoked at least 10 cigarettes daily for at least 6 months and intended to quit
3.6 g12 weeks46
New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E: A Randomized Controlled Trial
2025 · group 2 · Patients with nonalcoholic steatohepatitis (NASH); age and sex not stated
2.4 g26 weeks45
Effects of N-acetyl cysteine and melatonin on early reperfusion injury in patients undergoing coronary artery bypass grafting: A randomized, open-labeled, placebo-controlled trial
2018 · N-acetyl cysteine group · Adults aged 39–76 with ischemic heart disease undergoing coronary artery bypass grafting; non-diabetic and with normal left ventricular function
1.8 g2 days28
The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography
2003 · NAC group · Patients with chronic renal failure and serum creatinine concentration above 10(6) micromol/L undergoing coronary angiography
2 g2 days24
Comparative Study to Evaluate the Effect of Low-Protein Diet Supplementation with Taurine and N-Acetylcysteine, N-Acetylcysteine and Pyridoxamine Dihydrochloride in Preventing the Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney Disease
2022 · NT (taurine + NAC) arm · Adults with non-diabetic chronic renal failure, GFR >15 and <60 ml/min/1.73 m², receiving standard care
300 mg26 weeks23
N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study
2012 · N-acetylcysteine condition · 8 cocaine-dependent patients and 14 healthy controls
2.4 g1 day22
Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study
2015 · NAC · Adults with metabolic-syndrome risk factors, including abdominal obesity and at least two additional risk factors; 5 men and 15 women overall
200 mg3 weeks20
Acute exposure to traffic-related air pollution alters antioxidant status in healthy adults
2020 · antioxidant · Healthy adults; age range and sex not specified; no chronic medical condition
1.2 g7 days19
Effect of Oral N-Acetylcysteine Supplementation on the Immunity System in Patients with Acute Myocardial Infarction
2019 · NAC group · Patients with ST-segment elevation acute myocardial infarction who received fibrinolytic therapy
1.8 g3 days17
N-acetylcysteine as an adjunctive treatment for smoking cessation: a randomized clinical trial
2020 · NAC group · Adults aged 18–65 of either sex with tobacco use disorder who continued smoking or had not reduced cigarettes after four weeks of smoking-cessation treatment
1.8 g12 weeks17
MicroRNA expression in response to controlled exposure to diesel exhaust: attenuation by the antioxidant N-acetylcysteine in a randomized crossover study
2013 · DE exposure plus N-acetylcysteine (DEN) · Adults aged 19–35 with stable physician-diagnosed asthma and/or airway hyperresponsiveness
1.8 g6 days13
N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions
2011 · Arm 2, 35 mg/kg NAC solution · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease
35 mg/kg1 day10
N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions
2011 · Arm 2, 70 mg/kg NAC solution · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease
70 mg/kg1 day10
N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions
2011 · Arm 2, 140 mg/kg NAC solution · Healthy adults aged 21–55 years, both sexes, without acute illness or chronic disease
140 mg/kg1 day10
N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial
2018 · NAC · Men and women aged 18–38 with early-phase psychosis, with under 12 months of treatment for psychosis
2.7 g26 weeks10
A randomized, placebo-controlled pilot trial of N-acetylcysteine on oxidative stress and endothelial function in HIV-infected older adults receiving antiretroviral treatment
2016 · PharmaNAC 900mg twice daily · HIV-infected adults aged 50 years or older receiving virologically suppressive antiretroviral treatment
1.8 g8 weeks9
N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study
2019 · NAC arm · Patients with early psychosis; mean age 25 ± 6 years; men and women
2.7 g26 weeks9
Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study
2024 · NAC · Adults with bronchiectasis; age range and sex not specified
2.4 g6 weeks9
The effects of N-acetyl cysteine on intrinsic functional connectivity and neural alcohol cue reactivity in treatment-seeking individuals with alcohol use disorder: a preliminary study
2025 · NAC · Adults aged 18–70 with DSM-5 alcohol use disorder who wanted to reduce or stop drinking
2.4 g4 weeks9
Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial
2012 · NAC condition · Adults aged 31–35 with schizophrenia; nine men and two women were recruited, and eight completed the study
2 g8 weeks8
A randomized, placebo-controlled pilot trial of N-acetylcysteine on oxidative stress and endothelial function in HIV-infected older adults receiving antiretroviral treatment
2016 · PharmaNAC 1800mg twice daily · HIV-infected adults aged 50 years or older receiving virologically suppressive antiretroviral treatment
3.6 g8 weeks8
[Assessment of lipid peroxidation in hyperbaric oxygen therapy: protective role of N-acetylcysteine]
1995 · group B · Patients receiving hyperbaric oxygen therapy; age and sex not specified
1.8 g—7
Effect of cysteine derivatives administration in healthy men exposed to intense resistance exercise by evaluation of pro-antioxidant ratio
2007 · N-acetylcysteine (NAC) · Healthy men exposed to intense resistance exercise
1.8 g3 days—
Effects of sulphur-containing compounds on plasma redox status in muscle-damaging exercise
2009 · N-acetylcysteine (NAC) · Healthy, trained men
1.8 g3 days—
Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease
2010 · 1200 mg sustained-release NAC · Adults with end-stage renal disease
2.4 g2 weeks—
Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome
2011 · N-acetyl-cysteine (NAC) · Women with polycystic ovary syndrome (PCOS)
1.8 g24 weeks—
Effect of N-acetylcysteine administration on the expression and activities of antioxidant enzymes and the malondialdehyde level in the blood of lead-exposed workers
2014 · NAC 200 mg/day · Lead-exposed workers; age and sex not specified
200 mg12 weeks—
N-Acetylcysteine supplementation reduces oxidative stress and DNA damage in children with β-thalassemia
2014 · NAC group · Children with transfusion-dependent β-thalassemia
10 mg/kg90 days—
Effect of N-acetylcysteine administration on homocysteine level, oxidative damage to proteins, and levels of iron (Fe) and Fe-related proteins in lead-exposed workers
2016 · 1 × 200 mg NAC group · Male employees exposed to lead through their work
200 mg12 weeks—
Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status
2015 · NAC treatment, hyperlipidemic group (HYL) · Unmedicated middle-aged men with hyperlipidemia, stratified by smoking status
1.8 g4 weeks—
Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status
2015 · NAC treatment, normolipidemic group (NOL) · Unmedicated middle-aged normolipidemic men, stratified by smoking status
1.8 g4 weeks—
Effects of Selenium and/or N-Acetyl-Cysteine Supplementation on Nonthyroidal Illness Syndrome in Hemodialysis Patients: A Factorial Randomized Controlled Trial
2022 · group B · Hemodialysis patients with nonthyroidal illness syndrome; age and sex not specified
600 mcg12 weeks—
N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study
2022 · NAC group · Patients with schizophrenia or schizoaffective disorder
2.4 g8 weeks—
Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial
2015 · COM · Adults with at least moderate renal impairment undergoing cardiac catheterisation with or without percutaneous coronary intervention; mean age 68 years, 76% male
2.4 g3 days181
Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls
2005 · type 2 diabetes group · Adults with early-stage, untreated type 2 diabetes
600 g15 days46
Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls
2005 · impaired glucose tolerance group · Adults with impaired glucose tolerance
600 g15 days46
Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls
2005 · healthy control group · Healthy adults
600 g15 days46
Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial
2025 · Vit D 1000 + NAC (D1N) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m²
600 mg8 weeks22
Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial
2025 · Vit D 5000 + NAC (D5N) · Adults aged 65–82 years with vitamin D deficiency and BMI 25–35 kg/m²
600 mg8 weeks22
Blood oxidative stress biomarkers in women: influence of oral contraception, exercise, and N-acetylcysteine
2022 · NAC trial · Recreationally active women aged 18–35 with natural regular menstrual cycles or using combined monophasic oral contraception
105 mg/kg1 day20
N-Acetylcysteine improves the disturbed thiol redox balance after methionine loading
2003 · Met+NAC group · Healthy volunteers; age and sex not reported
1.8 g1 day18
Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study
1998 · Group A · Antiretroviral-naive adults with HIV infection at CDC'93 stages I and II
1.8 g24 weeks13
N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data
2016 · NAC group · Adults aged 40–80 with Parkinson’s disease, Hoehn and Yahr stage I–III, on a stable medication regimen
1.2 g90 days12
Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study
1998 · Group B · Antiretroviral-naive adults with HIV infection at CDC'93 stages I and II
1.8 g12 weeks11
Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress
2010 · N-acetylcysteine group · Adult hemodialysis patients
1.2 g10 days—
N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease
2019 · NAC group · Patients with Parkinson's disease
1 g90 days—
Effects of Selenium and/or N-Acetyl-Cysteine Supplementation on Nonthyroidal Illness Syndrome in Hemodialysis Patients: A Factorial Randomized Controlled Trial
2022 · group D · Hemodialysis patients with nonthyroidal illness syndrome; age and sex not specified
600 mcg12 weeks—
Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study
2017 · N-acetylcysteine group · Adults aged 18–50 who were treatment-seeking and met criteria for cannabis dependence
2.4 g12 weeks—